Insilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors

  • Post author:
  • Post category:uncategorized

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical-stage drug discovery company, today announced the nomination of ISM8001, a novel molecule targeting FGFR2/3 for the treatment of tissue-agnostic solid tumors…

Continue ReadingInsilico Medicine develops new AI-generated FGFR2/3 inhibitor for tissue-agnostic solid tumors